Next-Generation Nucleotide Therapeutics for Viral Infections and Cancer

A paradigm-shifting approach to nucleotide therapeutics, leveraging microneedle-based delivery, wearable devices, and nanoparticle-based systems to selectively target virally encoded RNA-dependent RNA polymerase (RdRp) and cancer cells, offering enhanced efficacy and convenience.

The original patent disclosed pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections. However, these compositions have limitations in terms of delivery, efficacy, and targeting specificity. The new inventive concept addresses these limitations by introducing novel delivery systems, conjugate compounds, and sulfur-containing bases that selectively target RdRp and cancer cells, providing a more effective and convenient treatment option.

The new inventive concept encompasses four main aspects: 1) microneedle-based delivery systems for transdermal administration of nucleotide or nucleoside therapeutic compositions; 2) wearable devices that release the compositions through transdermal patches; 3) conjugate compounds comprising sphingolipid or derivatives linked by phosphorus oxide to nucleotides or nucleosides, with sulfur-containing bases that selectively target RdRp; and 4) nanoparticle-based delivery systems for targeted treatment of cancer. These innovations enable more efficient, targeted, and patient-friendly treatment options for viral infections and cancer.

The new claims introduce novel delivery systems, conjugate compounds, and sulfur-containing bases that selectively target RdRp and cancer cells, which are not anticipated by the original patent. The inventive step lies in the combination of these elements to create a more effective, convenient, and targeted treatment approach.

Alternative embodiments may include using different types of wearable devices, varying the composition of the conjugate compounds, or incorporating additional targeting moieties. Variations may also involve adapting the delivery systems for different types of viral infections or cancer.

The next-generation nucleotide therapeutics have vast commercial potential in the treatment of viral infections and cancer, with a projected market size of billions of dollars. The inventive concept can be applied in various industries, including pharmaceuticals, biotechnology, and medical devices, offering opportunities for partnerships, licensing, and spin-offs.